ALKS

34.84

0.60% -0.21

Dopo l'orario di chiusura: 34.84

Alkermes Plc (ALKS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ALKS Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$35.05

Aprire:

$34.58

Volume 24 ore:

2.48M

Relative Volume:

1.08

Capitalizzazione di mercato:

$5.81B

Reddito:

$1.48B

Utile/perdita netta:

$241.66M

Rapporto P/E:

24.32

EPS:

1.4325

Flusso di cassa netto:

$480.33M

1 W Prestazione:

+16.44%

1M Prestazione:

+15.17%

6M Prestazione:

+11.45%

1 anno Prestazione:

+6.71%

Intervallo 1D:

$34.31

$35.32

Intervallo di 1 settimana:

$29.14

$36.48

Portata 52W:

$25.16

$36.48

Alkermes Plc Stock (ALKS) Company Profile

Nome

Alkermes Plc

Settore

Healthcare (1118)

Industria

Drug Manufacturers - Specialty & Generic (84)

Telefono

00-353-1-772-8000

Indirizzo

CONNAUGHT HOUSE, DUBLIN 4

Dipendente

2,050

Cinguettio

@alkermes

Prossima data di guadagno

2024-10-24

Ultimi documenti SEC

ALKS's Discussions on Twitter

Compare ALKS vs TAK, ZTS, HLN, TEVA, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ALKS Alkermes Plc	34.84	5.81B	1.48B	241.66M	480.33M	1.4325
TAK Takeda Pharmaceutical Co Adr	18.74	59.20B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	117.94	49.79B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.93	44.27B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	30.08	35.03B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	564.81	24.75B	3.18B	1.33B	1.04B	27.90

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-02-24	Iniziato	Wolfe Research	Outperform
2025-11-11	Iniziato	Truist	Buy
2025-09-26	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2025-09-03	Iniziato	Wells Fargo	Overweight
2025-07-15	Iniziato	Goldman	Buy
2025-06-17	Aggiornamento	UBS	Neutral → Buy
2025-05-28	Iniziato	Needham	Buy
2025-03-13	Iniziato	RBC Capital Mkts	Sector Perform
2025-03-04	Aggiornamento	UBS	Sell → Neutral
2025-02-11	Iniziato	Deutsche Bank	Buy
2024-11-05	Aggiornamento	Stifel	Hold → Buy
2024-06-17	Iniziato	TD Cowen	Buy
2024-03-19	Iniziato	Robert W. Baird	Outperform
2024-02-20	Downgrade	UBS	Neutral → Sell
2023-11-20	Ripresa	JP Morgan	Neutral
2023-10-24	Aggiornamento	Evercore ISI	In-line → Outperform
2023-10-17	Iniziato	UBS	Neutral
2022-11-03	Aggiornamento	Piper Sandler	Neutral → Overweight
2022-10-14	Aggiornamento	BofA Securities	Underperform → Neutral
2022-08-16	Iniziato	Piper Sandler	Neutral
2022-04-22	Ripresa	Goldman	Buy
2022-04-20	Iniziato	Goldman	Buy
2022-01-27	Aggiornamento	Cantor Fitzgerald	Hold → Overweight
2021-12-01	Iniziato	Citigroup	Neutral
2021-10-07	Aggiornamento	Jefferies	Hold → Buy
2021-09-02	Downgrade	BofA Securities	Neutral → Underperform
2020-10-15	Aggiornamento	Mizuho	Neutral → Buy
2020-07-30	Downgrade	Goldman	Neutral → Sell
2020-02-14	Downgrade	BofA/Merrill	Buy → Neutral
2020-02-14	Reiterato	H.C. Wainwright	Neutral
2020-02-14	Downgrade	JP Morgan	Overweight → Neutral
2020-02-06	Iniziato	Mizuho	Neutral
2020-01-31	Aggiornamento	Wolfe Research	Underperform → Peer Perform
2019-09-05	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2019-07-15	Aggiornamento	Goldman	Sell → Neutral
2019-05-31	Iniziato	H.C. Wainwright	Neutral
2019-05-01	Downgrade	Citigroup	Buy → Neutral
2018-12-19	Downgrade	Goldman	Neutral → Sell
2018-12-14	Iniziato	Wolfe Research	Underperform
2018-12-13	Downgrade	Credit Suisse	Outperform → Underperform
2018-11-05	Iniziato	Piper Jaffray	Neutral
2018-08-07	Iniziato	Stifel	Hold
2018-06-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight
2018-06-06	Iniziato	B. Riley FBR, Inc.	Buy
2018-05-16	Aggiornamento	Citigroup	Neutral → Buy
2018-05-11	Iniziato	BofA/Merrill	Buy

Mostra tutto

Alkermes Plc Borsa (ALKS) Ultime notizie

Apr 03, 2026

Alkermes Starts Phase 3 Program for Narcolepsy Drug Candidate Alixorexton - sleepreviewmag.com

Apr 03, 2026

Apr 02, 2026

Craig Hopkinson Sells 9,000 Shares of Alkermes (NASDAQ:ALKS) Stock - MarketBeat

Apr 02, 2026

ALKS Stock Price, Quote & Chart | ALKERMES PLC (NASDAQ:ALKS) - ChartMill

Apr 02, 2026

Alkermes plc (NASDAQ:ALKS) Launches Phase II Trial of ALKS 2680 for Idiopathic Hypersomnia - MSN

Apr 02, 2026

Top 2 Health Care Stocks That May Implode In April - Sahm

Apr 02, 2026

Apr 01, 2026

Alkermes launches phase 3 trials for narcolepsy drug alixorexton By Investing.com - Investing.com Australia

Apr 01, 2026

Alkermes stock hits 52-week high at $36.46 By Investing.com - Investing.com Canada

Apr 01, 2026

Alkermes launches phase 3 trials for narcolepsy drug alixorexton - Investing.com

Apr 01, 2026

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2 - finance.yahoo.com

Apr 01, 2026

Alkermes (ALKS) Nears 52-Week High on Increasing Orexin Receptor Market Interest - Insider Monkey

Apr 01, 2026

Mar 31, 2026

10 Stocks Dominating Today’s Market Surge: ImmunityBio, Alkermes, and More - Insider Monkey

Mar 31, 2026

Highs Report: What is the target price for Alkermes plc stockEntry Point & Technical Pattern Based Signals - baoquankhu1.vn

Mar 31, 2026

Lilly shifts from obesity to narcolepsy with $7.8B Centessa buy - BioWorld MedTech

Mar 31, 2026

Alkermes Shares Surge 15% Following Lilly-Centessa Deal - intellectia.ai

Mar 31, 2026

Alkermes’ Future: Critical Developments and Financial Outlook - timothysykes.com

Mar 31, 2026

Alkermes (ALKS) Shares Surge by Nearly 18% in Market Rally - GuruFocus

Mar 31, 2026